News Overview

The contract is for executing KAVACH, an indigenous train collision avoidance system, in 778 route kilometers in the Bengaluru and Mysuru divisions.

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

The issue may be done through public offers or private placements. This subject to market conditions, and regulatory approvals, stated the public lender.

The company also said that its board has recommended a final dividend of ₹1.5 per equity share for the FY25.

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Here are some of the stocks that may see significant price movement today.

Nearly 66% of full year hybrid fund flows in FY25 came in the first half of the financial year

April 2025 core sector growth was the lowest in 8 months as oil and fertilizers disappointed

On May 20, Indian Markets tumble on rising bond yields and fears of covid resurgence.

The Board of Directors of Texmaco has recommended a final dividend of ₹0.75 per equity share of face value of ₹1 (i.e. 75%) for the fiscal year ending March 31, 2025.